Salute e Benessere

DOSIsoft PLANET® Onco Dose receives CE MDR Mark and new FDA 510(k) clearance

This advanced software version allows clinics to cover a broader range of therapies by supporting voxel-based dose computation for 90Y, ¹⁷⁷Lu ¹⁶⁶Ho and ¹³¹I isotopes with the flexibility to incorporate new beta/gamma emitters. This advanced software version allows clinics to cover a broader range of therapies by supporting voxel-based dose computation for 90 Y, ¹⁷⁷Lu ¹⁶⁶Hoand¹³¹Iisotopes with the flexibility to incorporate new beta/gamma emitters. Clinicians can benefit from...
PR Newswire
07/04/2025

Transactions In Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from March 31 to April 4, 2025: Trading Platform...
Nasdaq GlobeNewswire
07/04/2025

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric…

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options 1 These efforts underscore Teva's dedication to expanding...
Nasdaq GlobeNewswire
07/04/2025

SUNWAY HEALTHCARE GROUP NAMED BEST INTEGRATED HEALTHCARE PROVIDER, SOUTHEAST…

Jay Reddy, CEO of Global Brands Magazine, commented, "We are proud to celebrate excellence across industries at Global Brands Magazine. Sunway Healthcare Group's recognition as the Best Integrated Healthcare Provider in Southeast Asia for 2024 reflects their exceptional commitment to innovation, transparency, and superior patient care. Congratulations to the entire team for this well-deserved achievement." Jay Reddy, CEO of Global Brands Magazine, commented, "We are proud to…
PR Newswire
07/04/2025

Transactions under Novonesis' share buyback program

Please read the announcement in PDF Attachment 2025_17_Share_buyback_program
Nasdaq GlobeNewswire
07/04/2025

Over 250 million people worldwide unaware they have diabetes, according to new…

The latest IDF estimates show that: The latest IDF estimates show that: As the number of people living with diabetes continues to rise, the latest IDF Diabetes Atlas emphasises the urgent need for improved prevention, early detection and intervention to tackle the burden diabetes places on individuals, communities, health systems and economies. In 2024, global diabetes-related health expenditure surpassedone trillion US dollarsfor the first time, up from$966 billionin 2021. First...
PR Newswire
07/04/2025

FIECON Joins Herspiegel to Expand Global Life Science Commercialization Services

This strategic integration expands Herspiegel's proven market access capabilities and enhances Herspiegel's global footprint. The integrated global access services will support patient access to life-saving and life-altering therapies through industry-leading expertise across the access value chain including strategy, health economic modeling, outcomes research, Health Technology Assessments (HTA), value communications, pricing and reimbursement, and Real-World Evidence (RWE). This strategic...
PR Newswire
07/04/2025

Temu Strengthens Commitment to Quality Assurance with Eurofins Consumer Products…

As part of this initiative, Eurofins Assurance will conduct independent inspection services across multiple product categories, including textiles, apparel, jewellery, toys, outdoor furniture, and electrical products. These assessments will help ensure that items available on Temu comply with relevant safety and quality regulations before reaching consumers. As part of this initiative, Eurofins Assurance will conduct independent inspection services across multiple product categories…
PR Newswire
07/04/2025

Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

The nine study participants were treated for varying durations, averaging 11 months per participant, including one individual treated under a compassionate use protocol with comparable dose ranges. Multiple statistical methods were applied to assess the results of this study, primarily through comparison with PRO-ACT, the largest ALS clinical trials dataset available. The nine study participants were treated for varying durations, averaging 11 months per participant, including one individual...
PR Newswire
07/04/2025

LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer

Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 –LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and world leader in neutrophil immuno-therapies, today announces the appointment of Mark A. Exley, PhD as Chief Scientific Officer (CSO), effective 7 April. The appointment of a CSO with extensive clinical expertise comes at a pivotal time for LIfT, as the Company prepares for clinical trials...
Nasdaq GlobeNewswire
07/04/2025

Duality Bio Appoints Hua Mu as Global Chief Medical Officer

"Dr. Mu's appointment comes at a pivotal moment as DualityBio approaches a new milestone in the capital markets," said Dr. John Zhu, Founder and CEO of DualityBio. "His unique blend of full-cycle development experience in multinational pharma and hands-on expertise in the globalization of China's innovative drugs will strengthen our global multicenter clinical trial strategy. By implementing scientifically rigorous clinical development plans, we will enhance pipeline value and…
PR Newswire
07/04/2025

Ypsomed and Sidekick Health launch a collaborative digital health solution for…

The challenge of obesity: support for a complex chronic conditionObesity is a complex, multifaceted chronic condition that demands holistic care and affects hundreds of millions of people worldwide. Despite the transformative potential of GLP-1 therapies, many patients struggle with selfcare-management. They face challenges such as managing side effects, understanding their condition, and adhering to medication titration schedules. As a result, many fail to reach their therapeutic potential…
PR Newswire
07/04/2025

Philips Applauded by Frost & Sullivan for Improving Imaging Quality and…

Philips CT 3500 addresses the operational challenges of healthcare facilities, especially those in regions with growing patient populations. Its design allows for higher patient throughput without demanding significant increases in power or space, enabling hospitals with limited resources to manage larger patient loads efficiently while maintaining high standards of care. The Philips CT 3500 includes automation features that can help improve workflow efficiency and assist in streamlining the…
PR Newswire
07/04/2025

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK…

- ABL Bio to receive up to £77 million in upfront and near-term payments - ABL Bio to receive up to £77 million in upfront and near-term payments SEONGNAM,South Korea , April 7, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing...
PR Newswire
07/04/2025

George Clinical Rebrands as Emerald Clinical Trials

Emerald Clinical Trials continues to focus on end-to-end services across all therapeutic areas designed to change lives⁠ while ⁠advancing innovations that help evolve global clinical research practices. With its strong track record in Oncology and Cardio-Renal-Metabolic (CRM) therapeutic areas, trusted expertise in Asia Pacific, and global scientific leadership, Emerald Clinical Trials is a highly differentiated clinical CRO on the world stage. The company's extensive reach – operating directly…
PR Newswire
07/04/2025

BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL…

Exploration of Nature at Shortest Distances Exploration of Nature at Shortest Distances Proof of Geometric Langlands Conjecture Special Prize Awarded to Giant of Theoretical Physics Breakthrough Prize in Life Sciences Awarded toDaniel J. Drucker,Joel Habener,Jens Juul Holst,Lotte Bjerre Knudsenand Svetlana Mojsov; Alberto Ascherio and Stephen L. Hauser; andDavid R. Liu Breakthrough Prize in Fundamental Physics Awarded to More than 13,000...
PR Newswire
06/04/2025

Dr. Bashar Bizrah Introduces Groundbreaking Facelift Technique in MENA Region

Innovative Focus on Safety and Precision Innovative Focus on Safety and Precision A key feature of Dr. Bizrah's technique is the integration of real-time facial nerve monitoring during surgery. This technology enables surgeons to track facial nerve activity throughout the procedure, ensuring high precision and reducing the risk of nerve injury. This advancement allows for immediate adjustments during the surgery, safeguarding the natural movement and expression of the face. "We don't...
PR Newswire
05/04/2025

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published…

Rapid, potent and sustained control of nasal symptoms: Rapid, potent and sustained control of nasal symptoms: Rapid relief of nasal obstruction： Compared to placebo group, patients in stapokibart group achieved significantly greater improvement in nasal congestion symptom at Day 2. By Day 7, 72% of patients reported clear nasal breathing, with the cumulative response rate rising to 86% at Week 2 and 94% at Week 4. Potent and sustained control of nasal symptoms： Stapokibart...
PR Newswire
05/04/2025

BIZCLIK MEDIA PUBLISHES APRIL EDITION OF HEALTHCARE DIGITAL

Inside this issue: Inside this issue: Stay ahead of industry developments and explore more insights at Healthcare Digital . About BizClik BizClik is one of the fastest-growing digital media companies in the UK, host to a growing portfolio of industry-leading global brands and communities. BizClik's expanding portfolio includes Technology, AI, FinTech, InsurTech, Supply Chain, Procurement, Energy, Mining, Manufacturing, Healthcare, Mobile, Data Centre, Cyber, and...
PR Newswire
04/04/2025

US Autoinjectors Market worth US$1.45 billion in 2030 with 14.2% CAGR |…

Browse in-depth TOC on "US Autoinjectors Market" Browse in-depth TOC on "US Autoinjectors Market" 150 - Tables 50 - Figures By Based on the therapy area,the autoinjectors market is divided into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity, and other therapy areas. In 2023, the rheumatoid arthritis segment dominated the autoinjectors market, and the obesity segment is...
PR Newswire
04/04/2025

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Definitive Agreementwith Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate thepreviously announcedintegration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States.Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. (“POI”) dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025 (collectively, the “Binding...
Nasdaq GlobeNewswire
04/04/2025

SkylineDx Presents Landmark Study on Merlin CP-GEP beyond SLNB prediction…

While SLNB remains the standard for melanoma staging, many patients classified as low-risk based on traditional methods still experience relapse or even death. The CP-GEP model, which combines gene expression data with clinical factors age and tumor thickness, effectively identified two distinct risk groups among patients who did not undergo SLNB. While SLNB remains the standard for melanoma staging, many patients classified as low-risk based on traditional methods still experience relapse or…
PR Newswire
04/04/2025

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary…

Company ") on 27 March 2025 regarding key information on the reverse share split at a ratio of 10:1.Radforsk Investeringsstiftelse (" Radforsk ") has previously agreed with the Company to make available, without any compensation a, necessary number of shares to ensure that all fractions of shares are rounded up to the nearest whole share, thus avoiding that shareholders will have its shareholdings rounded off downwards. Radforsk has today transferred a total of 1730 shares to DNB…
Nasdaq GlobeNewswire
04/04/2025

Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug…

As the global small nucleic acid drugs market rapidly expands, driven by growing demand for precise treatments targeting genetic disorders, rare diseases, and cancer. The high specificity of small nucleic acid drugs makes them particularly promising for rare diseases caused by single-gene mutations. However, this progress also comes with technical hurdles and increasingly stringent regulatory requirements. Amidst the surging market and growing regulatory challenges, Dr. Yaning Wang joins Tsingke…
PR Newswire
04/04/2025
Altri  Comunicati